Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

FDA Approves First Artificial Pancreas Medical Device For Type 1 Diabetes

XTALKS VITALS NEWS

Medical Device

The device – Medtronic’s MiniMed 670G – is a hybrid closed loop system approved for use in patients over the age of 14.

Tweetables from this article:

Tweet: Medtronic’s SmartGuard HCL algorithm automates #glucosemonitoring and insulin dosing activities http://ctt.ec/83XeE+ Medtronic’s SmartGuard HCL algorithm automates glucose monitoring and insulin dosing activities.

Share this!

September 30, 2016 | by Sarah Hand, M.Sc.

This week the US Food and Drug Administration (FDA) approved the first artificial pancreas device, designed to automatically monitor glucose levels and administer insulin to patients with type 1 diabetes. The device – Medtronic’s MiniMed 670G – is a hybrid closed loop system approved for use in patients over the age of 14.

Patients with type 1 diabetes lack the ability to produce insulin in response to changing blood glucose levels. While the pancreas normally maintains a continuous level of insulin, those with type 1 diabetes often lack this basal level of the hormone in the blood.

“The FDA is dedicated to making technologies available that can help improve the quality of life for those with chronic diseases – especially those that require day-to-day maintenance and ongoing attention,” said Dr. Jeffrey Shuren, director of the FDA’s Center for Devices and Radiological Health. “This first-of-its-kind technology can provide people with type 1 diabetes greater freedom to live their lives without having to consistently and manually monitor baseline glucose levels and administer insulin.”



Comprised of a sensor which measures glucose levels under the skin, an insulin pump and an insulin infusion patch, the artificial pancreas adjusts insulin levels without the need for user input. The MiniMed measures glucose levels at five minute intervals, and only requires patients to manually adjust insulin doses after consuming a carbohydrate meal.

The medical device uses Medtronic’s SmartGuard HCL algorithm to automate glucose monitoring and insulin dosing activities. A customizable system, the MiniMed’s automation level can be changed based on physician and patient needs.

“With SmartGuard HCL, the ability to automate basal insulin dosing 24 hours a day is a much-anticipated advancement in the diabetes community for the profound impact it may have on managing diabetes - particularly for minimizing glucose variability and maximizing time in the target range,” said Dr. Richard M. Bergenstal, principal investigator of the pivotal study and executive director of the Park Nicollet International Diabetes Center in Minneapolis. “The data from the pivotal trial were compelling and I am confident that this therapy will be well-received by both the clinical and patient community.”

Approximately five percent of the diabetic community has type 1 diabetes, according to the US Centers for Disease Control and Prevention (CDC). Traditional management of the disease is very intensive, with patients needing to check their glucose levels consistently throughout the day, and self-administer insulin in order to avoid hyperglycemia.

“The FDA approval of the world's first hybrid closed loop system is a culmination of many years of hard work and close collaboration with the clinical and patient communities to generate the body of evidence needed to advance this technology for those living with diabetes,” said Dr. Francine Kaufman, chief medical officer of the Diabetes Group at Medtronic. “We appreciate the unprecedented speed by which the agency approved our PMA submission to help bring this advanced insulin pump therapy so quickly to U.S. patients living with this challenging disease. We are committed to preparing for commercial launch as quickly as possible while ensuring we provide the most successful rollout of this novel therapy.”


Keywords: FDA, Medical Device, Type 1 Diabetes


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Approach Could Allow Red Blood Cells to be Manufactured

March 27, 2017 - UK researchers at the University of Bristol have developed an immortal line of early adult erythroblasts capable of continuously producing mature red blood cells.

Featured In: Biotech News


Lung Cancer Recurrence Could Be Better Detected Using Biomarker Blood Test

March 24, 2017 - The results of a recent prospective clinical trial found that a biomarker blood test could detect lung cancer recurrence a full six months before imaging methods could spot the disease.

Featured In: Biotech News


Use of Testosterone Treatments Boosted by DTC Ad Campaigns

March 24, 2017 - Those with a stake in the pharmaceutical industry often question the effectiveness of direct-to-consumer (DTC) advertising, and whether it truly influences consumers to talk to their doctors about medical conditions and perhaps even ask for drugs by name.

Featured In: Pharmaceutical Marketing News

LEAVE A COMMENT
 
  
THE XTALKS VITALS LIFE SCIENCE BLOG

Will Pharmaceutical Serialization Solve All of Our Drug Counterfeiting Problems?

REGISTER FOR THESE WEBINARS

How to Improve the Speed and Efficiency of Your Clinical Trials


High Performance Computing for High Content Screening - A Case Study


The FDA Guidance on the Assessment of Abuse Potential of Drug – A Critical Review


Treatment of Psoriasis: Improvements Through Clinical Trials


Copyright © 2016-2017 Honeycomb Worldwide Inc.